This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
1p9t
From Proteopedia
Revision as of 23:41, 28 September 2014 by OCA (Talk | contribs)
A novel coronavirus has been identified as the causative agent of severe acute respiratory syndrome (SARS). The viral main proteinase (Mpro, also called 3CLpro), which controls the activities of the coronavirus replication complex, is an attractive target for therapy. We determined crystal structures for human coronavirus (strain 229E) Mpro and for an inhibitor complex of porcine coronavirus [transmissible gastroenteritis virus (TGEV)] Mpro, and we constructed a homology model for SARS coronavirus (SARS-CoV) Mpro. The structures reveal a remarkable degree of conservation of the substrate-binding sites, which is further supported by recombinant SARS-CoV Mpro-mediated cleavage of a TGEV Mpro substrate. Molecular modeling suggests that available rhinovirus 3Cpro inhibitors may be modified to make them useful for treating SARS.
Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs.,Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R Science. 2003 Jun 13;300(5626):1763-7. Epub 2003 May 13. PMID:12746549[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
↑ Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 2003 Jun 13;300(5626):1763-7. Epub 2003 May 13. PMID:12746549 doi:10.1126/science.1085658